physician-directed prescriptions and supported by processes for blood collection, preparation, storage, and home delivery. Ocubio also offers subscription plans aligned with treatment protocols to manage ongoing access to personalized ocular formulations. In addition, the company is developing OB-1, an investigational allogeneic human platelet lysate eye drop for dry eye disease, currently in early clinical trials. Ocubio supports both clinicians and patients with educational resources related to autologous and blood-derived ocular therapies.